(P061) Anticoagulation Use and Improved Outcomes in a Predominantly African-American Population With High-Risk Prostate Cancer

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In our population of predominantly minority men with HR disease, the use of anticoagulation is associated with improved bFS and DMFS on multivariate analysis. However, AA race was not associated with any differences in outcome.

Elliot B. Navo, MD, Shan-Chin Chen, Justin Rineer, MD, David Schreiber, MD; Department of Veterans Affairs, NY Harbor Healthcare System, SUNY Downstate Medical Center; MD Anderson Cancer Center Orlando

INTRODUCTION: Several studies have reported improved biochemical and prostate cancer–specific mortality (PSM) outcomes, particularly for men with high-risk (HR) disease, associated with the use of anticoagulation (AC), in addition to radiation therapy. Numerous other studies have suggested that prostate cancer in African-American (AA) men tends to be more aggressive than in Caucasians and/or other races. Therefore, we analyzed our cohort of predominantly AA men with HR disease to determine whether anticoagulation use is associated with any improvements in biochemical or clinical outcomes.

MATERIALS AND METHODS: There were 469 consecutive men treated at the New York Harbor Veterans Hospital with dose-escalated radiation therapy (minimum dose 7,560 cGy) for nonmetastatic prostate cancer between 2003 and 2010. Of these patients, 143 had HR disease and were included in this study. Men were categorized by use of AC at the time of consultation and/or follow-up examinations. Chi-square or Fisher’s exact test was used to compare patient characteristics. Kaplan-Meier curves were generated to compare biochemical-free survival (bFS), distant metastasis–free survival (DMFS), and PSM; outcomes were compared using the log-rank test. Multivariate Cox regression was also performed to identify covariates associated with increased risk for all clinical endpoints.

RESULTS: The median follow-up was 65 months. A total of 55.9% of patients were identified as AA. There were no significant differences in patient characteristics between +AC and −AC. There was significantly improved bFS for AC patients at 5 years (84.6% vs 65.1%; P = .048). The 5-year DMFS was 96.4% for +AC vs 92% for −AC (P = .069). The 5-year PSM was 96.1% for +AC vs 95.9% for −AC (P = .21). On multivariate analysis for biochemical control, only use of AC was associated with improved bFS (hazard ratio [HR] = 0.47; 95% confidence interval [CI], 0.23–0.95; P = .036). AA race was not a significant predictor for biochemical failure (HR = 1.50; 95% CI, 0.50–4.50; P = .47). Similarly, in regard to multivariate analysis for distant metastases, AC was associated with improved DMFS (HR = 0.24; 95% CI, 0.06–0.88; P = .03). However, in regard to PSM, there was no benefit associated with the use of AC (HR = 0.26; 95% CI, 0.05–1.32; P = .10).

CONCLUSIONS: In our population of predominantly minority men with HR disease, the use of anticoagulation is associated with improved bFS and DMFS on multivariate analysis. However, AA race was not associated with any differences in outcome. 

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content